Severe Toxicities in Lymphoma Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Severe Toxicities in Lymphoma Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

“Delveinsight Business Research LLP”
DelveInsight’s “Severe Toxicities in Lymphoma Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Severe Toxicities in Lymphoma Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lymphoma is a type of blood cancer that develops when white blood cells called lymphocytes grow out of control. Lymphoma is a broad term for cancer that begins in cells of the lymph system. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Non-Hodgkin and Hodgkin’s lymphoma involves different types of lymphocyte cells. Every type of lymphoma grows at a different rate and responds differently to a treatment.

The risk of developing many late effects can be reduced by following a healthy lifestyle such as giving up smoking, maintaining a healthy weight, reduction of chemotherapy dose, the use of less toxic chemotherapeutic agents, and the introduction of new radiation techniques.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/severe-toxicities-in-lymphoma

The Severe Toxicities in Lymphoma Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Severe Toxicities in Lymphoma market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Severe Toxicities in Lymphoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Severe Toxicities in Lymphoma Market

Severe Toxicities in Lymphoma Market Key Facts

  • According to WHO (2014), patients receiving chemotherapy for HL suffer from temporary alopecia, and myelosuppression, including suppression of the neutrophil count, increasing the risk of infection, although infection incidence remains low at 2%.

  • According to SEER, for Hodgkin lymphoma, 14.2% are diagnosed at stage I, 39% are diagnosed at stage II, 21% are diagnosed at stage III, 20% are diagnosed at stage IV and 5% are diagnosed at an unknown stage.

  • According to Gotti et al (2013), a study conducted on 32 patients with early-stage HL treated with 4 cycles of ABVD chemotherapy confirmed; a significant reduction in forced expiratory volume in 1 second (FEV1), forced expiratory flow at 25%–75% (FEF25–75%), total lung capacity (TLC), vital capacity (VC), and DLCO at the end of treatment was observed. Reduction in TLC, VC, and DLCO, a mirror of a restrictive type pulmonary defect, persisted one year after the end of therapy.

  • According to a study conducted by Baena-Gómez et al (2015), a total of 20 mature B-cell NHL cases were diagnosed. Almost two-thirds (65%) of patients were classified in a high-grade stage (III-IV) at diagnosis. Serious infectious processes, severe myelosuppression, liver abnormalities, and mucositis were the most frequent toxicities.

  • According to David J. Straus (2011), among 18,862 5-year HL survivors in cancer registries from the USA and Europe, the 30-year cumulative relative risks for secondary solid tumors was 18% for women and 30% for men, and the risks of breast and colorectal cancers were elevated 10-15 years before the age when routine screening is recommended.

  • According to Shanbhag & Ambinder (2018), lymphoma is the most common cancer diagnosed in adolescents (aged 15 to 19 years) accounting for 21% of new diagnoses.

Key Benefits of Severe Toxicities in Lymphoma Market Report

  • Severe Toxicities in Lymphoma market report provides an in-depth analysis of Severe Toxicities in Lymphoma Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Severe Toxicities in Lymphoma Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Severe Toxicities in Lymphoma current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Severe Toxicities in Lymphoma market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Severe Toxicities in Lymphoma Market

The Severe Toxicities in Lymphoma market size shall grow during the forecast period owing to the launch of novel therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Severe Toxicities in Lymphoma Market Size and Share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Severe Toxicities in Lymphoma Market Trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Severe Toxicities in Lymphoma Epidemiology

The epidemiology section covers insights about the historical and current Severe Toxicities in Lymphoma patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Severe Toxicities in Lymphoma Epidemiology Segmentation

  • Total Incident Cases of Lymphoma

  • Severe toxicities specific Cases of Lymphoma

  • Type-specific Cases of Lymphoma

  • Stage-specific Cases of Lymphoma

  • Severe toxicities specific treated Cases of Lymphoma

Request for Sample @ Severe Toxicities in Lymphoma Market

Severe Toxicities in Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Severe Toxicities in Lymphoma market or expected to get launched in the market during the study period. The analysis covers Severe Toxicities in Lymphoma market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Severe Toxicities in Lymphoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Severe Toxicities in Lymphoma market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Severe Toxicities in Lymphoma emerging therapies.

No recent development has been reported in this space for the Severe Toxicities in Lymphoma, although some companies have tried to evaluate the role of emerging therapies in treatment such as Angiocrine Biosciences, among others.

Angiocrine Biosciences is working on AB-205, a novel, experimental, cellular therapy intended for the treatment of toxicities related to high-dose chemotherapy with or without radiation. AB-205 is composed of endothelial cells genetically modified using the E-CEL technology.

Table of Content

1. Key Insights

2. Executive Summary 

3. Severe Toxicities in Lymphoma Competitive Intelligence Analysis

4. Severe Toxicities in Lymphoma Market Overview at a Glance

5. Severe Toxicities in Lymphoma Disease Background and Overview

6. Severe Toxicities in Lymphoma Patient Journey

7. Severe Toxicities in Lymphoma Epidemiology and Patient Population

8. Severe Toxicities in Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Severe Toxicities in Lymphoma Unmet Needs

10. Key Endpoints of Severe Toxicities in Lymphoma Treatment

11. Severe Toxicities in Lymphoma Marketed Products

12. Severe Toxicities in Lymphoma Emerging Therapies

13. Severe Toxicities in Lymphoma Seven Major Market Analysis

14. Attribute Analysis

15. Severe Toxicities in Lymphoma Market Outlook (7 major markets)

16. Severe Toxicities in Lymphoma Access and Reimbursement Overview

17. KOL Views on the Severe Toxicities in Lymphoma Market.

18. Severe Toxicities in Lymphoma Market Drivers

19. Severe Toxicities in Lymphoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/severe-toxicities-in-lymphoma

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/